Examples, including Ruxolitinib (JAK1 and JAK2 inhibitor), and tofacitinib (JAK3 inhibitor, approved for rheumatoid arthritis) are being evaluated in various clinical trials for psoriasis, inflammatory bowel disease, transplant rejection, and juvenile arthritis60. Here, JAK3 is linked to inflammatory bowel disease.